Home › Funds › Affinity Asset Advisors, LLC › TVTX

Affinity Asset Advisors, LLC position in TVTX

TRAVERE THERAPEUTICS INC · Health Care

Affinity Asset Advisors, LLC reported holding 300,000 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$17.7M, representing 0.82% of its reported portfolio and ranking #33 among its reported holdings. Affinity Asset Advisors, LLC has disclosed TVTX holdings in 11 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)300.00K sh
Reported value held$17.66M
Portfolio Weight0.82%
First reportedQ3 2023
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Affinity Asset Advisors, LLC's TVTX position evolved

Affinity Asset Advisors, LLC first disclosed a stake in TVTX in Q3 2023 at 100,000 shares (US$894K). The position peaked in Q3 2026 at 300,000 shares, worth US$17.7M. Across 11 filings, Affinity Asset Advisors, LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 300,000 shares valued at US$17.7M. Notable position changes include a 96% trim in Q4 2024 (shares rose 3% over the following quarter), a 3400% increase in Q1 2025 (shares fell 17% over the following quarter), a 96% trim in Q1 2026 (shares rose 91% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 100.00K $894.00K New
Q1 2024 125.00K $963.75K New
Q3 2024 5.00M $4.32M New
Q4 2024 200.00K $3.48M Reduce
Q1 2025 7.00M $6.99M Add
Q2 2025 7.00M $6.69M Hold
Q3 2025 7.00M $7.93M Hold
Q4 2025 7.00M $9.99M Hold
Q1 2026 300.00K $8.91M Reduce
Q2 2026 300.00K $17.04M Hold
Q3 2026 300.00K $17.66M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TVTX and 13F data

TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 57 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$123.8M), Kynam Capital Management, LP (US$113.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TVTX

All TVTX fund holders →

FAQ

How long has Affinity Asset Advisors, LLC held TVTX?

Affinity Asset Advisors, LLC has disclosed TVTX holdings in 11 of the last 13 reported quarters, going back to Q3 2023.

What is Affinity Asset Advisors, LLC's current position in TVTX?

As of Q3 2026, Affinity Asset Advisors, LLC holds 300.00K shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $17.66M, representing 0.82% of its reported portfolio and ranking #33.

Has Affinity Asset Advisors, LLC been buying or selling TVTX?

In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC held unchanged its position in TVTX. The position peaked in Q3 2026 at 300.00K shares.

Which other funds hold TVTX?

Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 57 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.